On July 8, 2024, Athinia and ASNA announced a collaboration to improve semiconductor manufacturing yields through enhanced data sharing and traceability of subcomponent parts. This partnership aims to innovate in the tracking of previously untraceable parts, important for reducing defects and enhancing yield rates. Athinia's data analytics and multi-party sharing will help ASNA optimize component performance and lower costs by providing insights into the entire lifecycle of these parts. The initiative will leverage advanced analytics and machine learning to improve wafer performance, offering valuable insights and potentially enhancing the overall quality and reliability of semiconductor components.
Summary not available.
EMD Serono, a healthcare business of Merck KGaA, announced significant research findings at the World Conference on Lung Cancer and ESMO Congress, highlighting advancements in immuno-oncology and DNA damage response. Key presentations included real-world evidence for avelumab in advanced urothelial carcinoma and insights on tepotinib's efficacy in METex14 skipping NSCLC patients. Berzosertib data from a Phase II study in small cell lung cancer showcased its potential. These findings aim to inform treatment decisions for challenging tumors, emphasizing the company's commitment to transformative cancer therapies.
Merck KGaA, Darmstadt, Germany, released topline results from the Phase II INTR@PID BTC 047 study of bintrafusp alfa in second-line treatment for patients with locally advanced or metastatic biliary tract cancer (BTC). The study involved 159 patients and showed an objective response rate (ORR) of 10.1%, which did not meet the regulatory threshold for submission. Despite the results, bintrafusp alfa's single-agent efficacy offers insights for future studies. An ongoing Phase II/III trial is assessing bintrafusp alfa combined with chemotherapy for BTC.